NASDAQ$OLMA
Olema Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Olema Pharmaceuticals reported a net loss of $30.4 million for the second quarter of 2024.
Olema Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported operating expenses of $33.5 million for the three months ended June 30, 2024, primarily driven by research and development activities advancing its lead product candidate palazestrant. The company ended the quarter with $16.9 million in cash and cash equivalents and $222.2 million in marketable securities, supporting its ongoing clinical development programs. No revenue was generated during the period as the company remains focused on non-commercial stage activities.
- Net loss for Q2 2024 was $30.4 million, compared to $20.1 million in Q2 2023, reflecting increased R&D spending.
- Research and development expenses totaled $29.1 million, up from $18.0 million year-over-year, due to advancement of palazestrant clinical trials.
- Cash, cash equivalents, and marketable securities stood at $239.1 million as of June 30, 2024, providing runway for ongoing operations.
- General and administrative expenses were $4.4 million, with the company maintaining a lean operational structure while progressing its pipeline.
Headline financials
Revenue & EPS history
Olema · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.1%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+7.5%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+17.0%
Q4 2019
Best reaction
-28.5%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2026 | -3.2% | -7.7% | -29.4% | |
| Q3 2025 | +4.1% | +0.6% | +267.4% | |
| Q2 2025 | +16.0% | +20.6% | +75.1% | |
| Q1 2025 | +2.1% | +9.6% | -11.0% | |
| Q4 2024 | -8.5% | +4.3% | +6.8% | |
| Q3 2024 | -9.7% | -27.9% | -47.2% | |
| Q1 2024 | -12.5% | -18.0% | +16.8% | |
| Q4 2023 | -6.6% | -11.2% | -15.8% | |
| Q3 2023 | -7.6% | -7.4% | -29.2% | |
| Q2 2023 | +15.3% | +14.0% | +24.7% | |
| Q1 2023 | +1.1% | +6.1% | -0.3% | |
| Q4 2022 | +0.0% | +0.3% | -15.4% | |
| Q3 2022 | -7.2% | +5.6% | -22.5% | |
| Q2 2022 | -28.5% | -29.4% | -23.1% | |
| Q1 2022 | -1.3% | -3.1% | +79.4% | |
| Q4 2021 | +17.0% | -2.2% | -5.9% | |
| Q4 2019 | +17.0% | -2.2% | -5.9% | |
| Q3 2021 | +1.1% | -1.9% | -61.9% | |
| Q3 2020 | +1.1% | -1.9% | -61.9% | |
| Q2 2021 | +3.4% | +1.9% | +11.2% | |
| Q2 2020 | +3.4% | +1.9% | +11.2% | |
| Q1 2021 | +11.9% | +14.8% | +35.8% | |
| Q4 2020 | -10.2% | -23.2% | -27.2% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro